Islet encapsulation may allow transplantation without immunosuppression, but thus far islets in large microcapsules transplanted in the peritoneal cavity have failed to reverse diabetes in humans. We showed that islet transplantation in confined wellvascularized sites like the epididymal fat pad (EFP) improved graft outcomes, but only conformal coated (CC) islets can be implanted in these sites in curative doses. Here, we showed that CC using polyethylene glycol (PEG) and alginate (ALG) was not immunoisolating because of its high permselectivity and strong allogeneic T cell responses. We refined the CC composition and explored PEG and islet-like extracellular matrix (Matrigel; MG) islet encapsulation (PEG MG) to improve capsule immunoisolation by decreasing its permselectivity and immunogenicity while allowing physiological islet function. Although the efficiency of diabetes reversal of allogeneic but not syngeneic CC islets was lower than that of naked islets, we showed that CC (PEG MG) islets from fully MHC-mismatched Balb/c mice supported long-term (>100 days) survival after transplantation into diabetic C57BL/6 recipients in the EFP site (750-1000 islet equivalents/mouse) in the absence of immunosuppression. Lack of immune cell penetration and T cell allogeneic priming was observed. These studies support the use of CC (PEG MG) for islet encapsulation and transplantation in clinically relevant sites without chronic immunosuppression.
Islet encapsulation may allow transplantation without immunosuppression, but thus far islets in large microcapsules transplanted in the peritoneal cavity have failed to reverse diabetes in humans. We showed that islet transplantation in confined wellvascularized sites like the epididymal fat pad (EFP) improved graft outcomes, but only conformal coated (CC) islets can be implanted in these sites in curative doses. Here, we showed that CC using polyethylene glycol (PEG) and alginate (ALG) was not immunoisolating because of its high permselectivity and strong allogeneic T cell responses. We refined the CC composition and explored PEG and islet-like extracellular matrix (Matrigel; MG) islet encapsulation (PEG MG) to improve capsule immunoisolation by decreasing its permselectivity and immunogenicity while allowing physiological islet function. Although the efficiency of diabetes reversal of allogeneic but not syngeneic CC islets was lower than that of naked islets, we showed that CC (PEG MG) islets from fully MHC-mismatched Balb/c mice supported long-term (>100 days) survival after transplantation into diabetic C57BL/6 recipients in the EFP site (750-1000 islet equivalents/mouse) in the absence of immunosuppression. Lack of immune cell penetration and T cell allogeneic priming was observed. These studies support the use of CC (PEG MG) for islet encapsulation and transplantation in clinically relevant sites without chronic immunosuppression.
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| INTRODUCTION
Islet transplantation can restore glucose homeostasis and prevent complications of type 1 diabetes (T1D). 1 Despite recent clinical success, the applicability of islet transplantation is limited by the need for chronic immunosuppression to inhibit undesired allogeneic and recurrent autoreactive immune responses against transplanted islets. Moreover, the use of chronic immunosuppression is the main cause of adverse events in islet transplantation, 2-4 resulting in islet transplantation offered only in the most severe cases of T1D. There is a strong need to develop novel strategies that would eliminate the need for chronic immunosuppression and make islet transplantation a viable option for patients with T1D. Islet encapsulation could allow transplantation without the need for chronic immunosuppression, thereby extending the procedure to a larger number of patients, including children. [5] [6] [7] Despite promising results with many different microencapsulation strategies showing protection to allogeneic and xenogeneic islets after transplantation without systemic immune suppression in mice, 8, 9 clinical trials have only proven safety, not long-term efficacy. [10] [11] [12] The majority of human trials have been conducted in the peritoneal cavity (intraperitoneal, IP) with capsules of uniform and large diameter (500-1500 μm, despite islets having a variable size between 50 and 350 μm). Clinical failure of those traditional encapsulation protocols may be associated with 2 critical factors: (1) transplant site and (2) capsule size. Islet central hypoxia is one of the main determinants of graft outcomes. 8 Minimizing hypoxia
by islet transplantation in well-vascularized sites and/or by minimizing capsule thickness may lead to better outcomes. We previously demonstrated that transplantation of encapsulated islets in confined and vascularized sites like the epididymal fat pad (EFP) improves the outcome of naked 13 and encapsulated islet grafts 14 in mice. However, curative doses of islets encapsulated in traditional capsules add up to hundreds of milliliters and cannot be transplanted in these confined sites, as they can accommodate only a few milliliters grafts.
We recently developed a method for coating islets with a uniformly thin hydrogel layer that conforms to the islet shape and that is independent of islet size: conformal coating. 15 Because the volume of conformal coated (CC) islet grafts is comparable to the volume of naked islets grafts, CC islets can be transplanted in confined well-vascularized sites in curative doses. We previously reported the design of the encapsulation device and of the CC hydrogels 15 using polyethylene glycol (PEG) because of its greater physicochemical stability compared to other encapsulation materials. 14 We showed that PEG functionalized with divinyl sulfone (PEG-dVS) and crosslinked with dithiothreitol (DTT) needed to be supplemented with a viscosity enhancer to allow formation of conformal coatings and for modulating the coating permeability, which is critical for CC islet functionality. 15 By using alginate (ALG) as a viscosity enhancer for PEG hydrogels for coatings we showed physiological glucose-stimulated insulin release (GSIR) from CC islets in vitro. Our previous work showed sustained graft viability and function for >100 days in vivo in syngeneic murine islet transplant models in the nonclinically applicable but commonly evaluated kidney subcapsular space (KD).
15
This CC platform has laid the groundwork for a novel approach to minimizing the capsule thickness and volume of encapsulated islet grafts through conformal coating, but has not been explored in allogeneic islet transplantation in clinically relevant sites without immunosuppression.
Here we have built on these results and refined the composition of conformal coatings to provide immunoisolation properties to CC islets in fully MHC-mismatched diabetic mice without any immunosuppression and in clinically applicable confined and well-vascularized sites.
| MATERIALS AND METHODS

| Islet isolation and culture, diabetes induction, and islet transplantation
Pancreatic islets were isolated and cultured as described previously.
15
Diabetes was induced in mice by administration of intravenous streptozotocin. Isolated islets were then transplanted under the kidney capsule (KD) or in the epididymal fat pad (EFP) of diabetic mice, as described elsewhere.
14,15 Pancreatic islets were resuspended in the PEG ALG DTT or PEG MG DTT solution at a 50,000 islet equivalents (IEQ)/ml concentration and conformal coated or digested with "enzyme" to obtain graft-associated immune cells for FACS analysis as described previously. 
| Encapsulation materials and methods
| Viability/functionality assays in vitro
Islet viability and oxygen consumption rate (OCR) measurement 14 GSIR and perfusion were performed as described previously. 
| Evaluation of capsule completeness and permeability
For completeness assessment, 2000 kDa FITC-Dextran (Sigma) was added to the hydrogel solution used for encapsulation or to CC media.
In addition, capsules were stained with anti-PEG antibody. Samples were imaged using a Leica SP5 confocal microscope. Permeability of CC hydrogels to FITC-Dextran of selected molecular weight was measured as described previously. 
| Cytokine production of CC islets
CC (PEG MG) and naked islets were cultured for 1, 2, 7, and 14 days after encapsulation and Multiplex Immunoassay (Affymetrix) was performed on the supernatants.
| Evaluation of CC capsules and explanted grafts by histology and flow cytometry
Explanted grafts were either fixed in formalin, paraffin embedded and thin-sectioned, or digested. 16 Hematoxylin and eosin (H&E) staining and immunostaining/imaging using a Leica SP5 confocal microscope was done using anti-PEG (Abcam), Hoechst (Molecular 
| Statistical analysis
Prism 6 was used for all data analysis. Data are presented as mean ± standard deviation (SD). Statistical analysis was performed as previously described. 14 
| RESULTS
| Conformal coating using PEG-dVS ALG hydrogels does not provide immunoisolation to rodent islets
Following promising results of CC using PEG ALG hydrogels in syngeneic islet transplant models at the KD site in mice, we investigated whether CC with PEG ALG provided immunoisolation to fully MHC-mismatched islet allografts. Two days after coating, we transplanted CC (PEG ALG) or naked Balb/c islets ( Figure 1A ) at the KD site of diabetic B6 mice (1000 IEQ/mouse). Unlike naked islets, which reversed diabetes and were then rejected (13-20 days), CC (PEG ALG islets) never reversed diabetes ( Figure 1B) . Analysis of islet viability ( Figure 1C ) and GSIR function ( Figure 1D ) at the time of transplantation showed no significant difference between the naked and the CC (PEG ALG) islets, suggesting that failure of CC (PEG ALG) islets to reverse diabetes was not due to poor viability or lack of functionality of CC Balb/c islets prior to transplantation. However, histological analysis of the CC (PEG ALG)-retrieved grafts showed only a few insulin-positive islets remaining at the graft site, with most capsules lacking any residual islets ( Figure 1E-F) , suggesting that CC islets were rejected after transplantation. Furthermore, unlike what we had observed previously for syngeneic CC grafts, 15 we found that macrophages were present on the majority of the capsule surface To further confirm that the mechanisms of CC graft loss was dependent on poor immunoisolation of PEG ALG hydrogels, we investigated the barrier properties of CC (PEG ALG) membranes to large (2000 kDa) FITClabeled dextran, either entrapped within coating hydrogels ( Figure 1N ) or added to the CC media ( Figure 1O ). We found that coatings presented a microporous structure, further supporting that lack of immunoisolation of CC (PEG ALG) hydrogels was an underlying mechanism for the failure of CC (PEG ALG) islet allografts. Therefore, we focused on refining the composition of CC capsules to improve immunoisolation of CC capsules and allow long-term allograft functionality in mice. 
| Refining the composition of CC hydrogels to improve immunoisolation
First, to develop a better strategy for CC in the transplant setting, we wanted to assess whether suboptimal biocompatibility of PEG ALG at the KD site, in addition to poor immunoisolation, was also contributing to the failure of CC (PEG ALG) allografts to reverse diabetes. We compared the host reactivity to control PEG-dVS capsules in the subcutaneous (SC), KD, and EFP site. We found that reactivity to PEG gels in the EFP site was lower (higher biocompatibility) than in the KD capsule and in the SC site as assessed by H&E staining showing fibrotic cell layers (Figure 2A ). Given the reactivity of empty PEG-dVS capsules, we next tested PEG functionalized with MAL, a more stable functional group that reacts with DTT to form hydrogels by a Michael type addition.
17
We found that PEG-MAL biocompatibility was higher than PEG-dVS in both the KD and SC sites ( Figure 2B ). Despite different coating biocompatibility, CC (PEG-dVS) and CC (PEG-MAL) islets displayed comparable viability ( Figure 2C ) and GSIR ( Figure 2D ) in vitro. Therefore, we selected PEG-MAL as coating composition for the studies that followed.
Next, we wanted to test a more biologically relevant material than ALG as a viscosity enhancer and additive for PEG-MAL hydrogels to improve the immunoisolating properties of CC. Because of the natural composition of islet-like extracellular matrix (ECM) and its role in preventing leukocyte infiltration of pancreatic islets in the native pancreas, 18 we replaced ALG with a commercially available reagent, Matrigel (or MG), which resembles the composition of islet ECM. We Unlike CC (PEG-dVS ALG), CC (PEG MG) was completely impermeable to high-molecular-weight dextran ( Figure 2I ). Despite lower permselectivity to 2 kDa dextran than to CC (PEG-dVS ALG), diffusion of lowermolecular-weight dextran through CC (PEG MG) was permitted with a diffusion kinetic that correlated with a dextran molecular weight ( Figure 2J ). In addition,, physiological insulin release of CC (PEG MG)
islets was observed during a 0.1 ml/min dynamic glucose challenge ( Figure 2K ). These results suggest that biocompatibility properties of CC can be enhanced by using PEG-MAL MG as hydrogel for CC islets. Moreover, minimal macrophage infiltration ( Figure 3G ) was also found, suggesting long-term biocompatibility of PEG MG hydrogel for CC.
| PEG-MAL MG CC islets transplanted in the EFP
These results overall demonstrated that conformal coating using PEG MG as hydrogel composition is immunoisolating. Analysis of grafts that failed to maintain long-term euglycemia indicated that graft failure was not due to loss of immunoisolation, since T and B lymphocytes were not found within CC (PEG MG) capsules ( Figure S1 A-D), unlike naked islet grafts ( Figure S1 E-H). Immunostaining of CC (PEG MG) with PEG antibodies confirmed that coatings were intact ( Figure 3H ). 
Phenotyping CD8
+ T cells from allo-MLR assays showed that proliferating CD8 responders from the naked and CC (PEG ALG) islet recipients are CD44 and Granzyme B + , consistent with activation and cytotoxic phenotype ( Figure 4E ). Collectively, these data suggest that the CC (PEG MG) islets were not only void of penetrating lymphocytes but also failed to prime CD8 allo-responses, which likely contributed to their long-term acceptance following diabetes reversal compared to the CC (PEG ALG) or naked islets.
| Decreased efficiency of diabetes reversal after transplantation of CC (PEG MG) islet allografts is dependent on host responses to CC islets but not to CC hydrogels
Although diabetes reversal was observed in some diabetic B6 mice transplanted with naked or CC (PEG MG) Balb/c islets, CC (PEG MG) islets overall did not reverse diabetes as efficiently as naked islets ( Figure 5A ). To investigate the mechanism underlying the suboptimal engraftment efficiency of CC allografts, we evaluated whether islets in PEG MG conformal capsules experienced loss of viability and/or GSIR function after encapsulation. We cultured naked and CC (PEG MG) Balb/c islets up to 14 days and found no significant difference in either viability or presence of reactive oxygen species (ROS) ( Figure 5B ) at 2, 7, and 14 days after encapsulation. GSIR index of CC (PEG MG) islets was significantly higher than that for naked islets both at day 2 and day 7 after encapsulation, while it was comparable at day 14 ( Figure 5C ). This suggested a beneficial effect of CC (PEG MG) on islet functionality and that reduced diabetes reversal rate of CC versus naked islets was not due to loss of viability or function. Therefore, we examined the host responses to CC (PEG MG) after transplantation. Because host responses may be mediated by PEG MG biomaterials themselves (biocompatibility) or by bioactive molecules secreted by CC (PEG MG) islets, we co-transplanted naked syngeneic B6 islets and cell-free empty PEG MG capsules into diabetic B6 recipient mice (750 IEQ/mouse). We saw no difference in diabetes reversal efficiency ( Figure 5D ) and long-term blood glucose control ( Figure 5E ) compared to naked islets or CC islets (n = 4 per condition; P = .127 and P = .18). Histological evaluation of CC (PEG MG) grafts 100 days after implantation in syngeneic recipients confirmed lack of macrophage accumulation and maintenance of islet architecture ( Figure 5F ). These results suggested that host immune responses to PEG MG hydrogels themselves were not the underlying cause of the reduced graft reversal efficiency of CC (PEG MG) islets.
Next, we examined whether secretion of proinflammatory and anti-inflammatory cytokines from CC (PEG MG) islets during in vitro culture were affected by coatings and whether this was time dependent. We found that interferon γ (IFNγ) (Figure 5L ), IL-1β ( Figure 5M ), IL-13 ( Figure 5N ), and MIP1α ( Figure 5O ) proinflammatory cytokine secretion was increased in CC compared to naked islets. IL-10
( Figure 5P ) and IL-4 ( Figure 5Q ) anti-inflammatory and Th2 cytokines secretion was reduced in CC compared to naked islets. In contrast, tumor necrosis factor α (TNFα) (Figure 5G ), MCP-1 ( Figure 5H ), IL1α
( Figure 5I ), IL-6 ( Figure 5J ), and IL-2 ( Figure 5K ) proinflammatory cytokine secretion was comparable or even reduced in CC compared to naked islets. Because the same mouse strain was used as recipient for allogeneic ( Figure 5A ) and syngeneic ( Figure 5D ) islets, these results suggest that host responses to CC (PEG MG) islets could be heightened in the presence of allogeneic islets in CC hydrogels, which in a portion of the mice prevented engraftment and diabetes reversal after transplantation of CC allogeneic, but not CC syngeneic islets.
Next, we analyzed the grafts 4 days after transplantation by immunohistochemistry to evaluate the presence of leukocytes at the transplant site. CC islets were found intact inside capsules and void of T cells, B cells, or macrophages within the capsules, which was in stark contrast to the transplanted naked islets ( Figure 6A ). However, we observed the presence of immune cells to the graft periphery of CC (PEG MG) islets. Quantification and phenotypic characterization of these infiltrates confirmed that higher numbers of CD45 + cells were present in both naked and CC islet grafts ( Figure 6B ) and higher numbers of macrophages in CC islet grafts ( Figure 6D ) compared to islet-free fibrin grafts. No differences in total number and relative proportions of T cells and other antigen-presenting cell subtypes were found. However, among the CD8 + T cells infiltrating CC grafts, F I G U R E 5 Decreased efficiency of diabetes reversal after transplantation of CC (PEG MG) islet allografts is dependent on host responses to CC islets but not to CC hydrogels. (A) Percentage of chemically induced diabetic B6 mice transplanted with 750-1000 IEQ naked (black, n = 18) or CC (PEG MG) (red, n = 31) islets from Balb/c mice that reversed diabetes after transplantation in the EFP site using fibrin scaffolds
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(***=P < .0001). (B) Confocal microscope images of live (calcein AM, green)/dead (ethidium homodimer, red)/nuclei (Hoechst, blue) staining (left) and reactive oxygen species (ROS, green)/nuclei (Hoechst, blue) staining (right) of naked (top panels) versus CC (PEG MG) (bottom panels) islets from Lewis rats assessed 2, 7, and 14 days after encapsulation (4, 9, and 16 days after isolation) and cultured in vitro (scale bars, 100 μm).
(C) GSIR index of naked (black) versus CC (PEG MG) (red) islets from Lewis rats evaluated 2, 7, and 14 days after encapsulation (4, 9, and 16 days after isolation, 3 replicates of 100 IEQ per condition) (Index naked vs. CC PEG MG: day 2 P = .0099, day 7 P = .014, day 14 P = .4064).
(D-F) Percentage of diabetes reversal (D), blood glucose (E), and histological analysis (F) of chemically induced diabetic B6 mice transplanted with 750 IEQ naked islets (naked, black, n = 4) or CC (PEG MG) islets (red, n = 4) or naked islets with islet-free empty PEG MG capsules (Naked + empty, orange, n = 4) from B6 mice in the EFP site using fibrin scaffolds. 
| DISCUSSION
Our overall goal is to develop an encapsulation platform that allows islet transplantation without immunosuppression, extending its applicability to a larger number of patients with T1D. Conformal coating encapsulation addresses some critical issues that may have led to clinical failure of traditional encapsulation protocols using traditional microcapsules in the IP site. Specifically, CC capsules allow transplantation of curative doses of encapsulated islets in confined well-vascularized sites, which we previously demonstrated to be superior to the IP site. 14 Here, we built on our previous work that established the novel procedure for conformal coating with PEG using suboptimal hydrogels. We found that those do not confer immunoisolation to islet allografts. In addition, that study was performed in nonclinically relevant transplant sites. In this report, we refined the composition of CC hydrogels and showed that CC using PEG hydrogels allows immunoisolation of islet allografts in clinically applicable confined and well-vascularized sites with high potential for clinical translation.
We previously reported the design of the encapsulation device and the properties of the CC hydrogels, which was based on PEG hydrogels, supplemented with ALG to increase the pre-polymer viscosity and modulate the coating permeability. 14 CC (PEG ALG) showed promising results in vitro and in vivo in syngeneic islet transplant models at the nonclinically relevant but most common transplant site in mice, products from stem cells.
21, 22
Despite the challenge in diabetes reversal, we demonstrated that conformal coating encapsulation is a valid platform to allow islet allotransplantation without immunosuppression. The main advantage of conformal coating encapsulation over other encapsulation strategies is the reduced graft volume, allowing CC islets to be transplanted into any site. This includes the intrahepatic site, biohybrid and/or pre-vascularized devices [23] [24] [25] [26] [27] and the biologic scaffold in the omental pouch (OP) site, 26 which are currently explored in a very promising human clinical trial with naked allogeneic islets and chronic immunosuppression (NCT02213003).
